每周一次胰岛素icodec与每日一次对照胰岛素在不同人口学亚组中的疗效与低血糖特征
该事后分析基于ONWARDS 1至5的3a期临床试验,评估年龄、族裔和种族对每周一次胰岛素icodec与每日一次基础胰岛素疗效及低血糖结局的影响。结果显示,在各年龄、族裔和种族亚组中,icodec与每日一次胰岛素的HbA1c变化估计治疗差异及达到HbA1c<7%且无临床显著或严重低血糖的比值比均相似,亚组交互作用均无统计学显著性(P>.05)。结论认为icodec与每日一次对照胰岛素的疗效和低血糖特征在各试验人群中不受年龄、族裔或种族影响。
要点
- 在各年龄、族裔和种族亚组中,icodec与每日一次胰岛素的HbA1c变化估计治疗差异相似。
- 达到HbA1c<7%且无临床显著或严重低血糖的比值比在各亚组间相似。
- 所有治疗与亚组交互作用均无统计学显著性(P>.05)。
核心结论
- icodec与每日一次对照胰岛素的疗效和低血糖特征在各试验人群中不受年龄、族裔或种族影响,表现一致。
研究设计与样本
- 基于ONWARDS 1至5的3a期临床试验数据的事后分析,纳入年龄≥18岁的2型糖尿病成人,包括胰岛素初治(ONWARDS 1、3和5)和胰岛素经治(ONWARDS 2和4)人群。
- 亚组包括年龄(<55、55-64和≥65岁)、族裔(西班牙裔/拉丁裔和非西班牙裔/拉丁裔)和种族(亚洲人、黑种人/非裔美国人、白种人、其他)。
- 主要结局为糖化血红蛋白(HbA1c)从基线至计划治疗结束的变化。
主要发现
- 在所有试验中,icodec与每日一次胰岛素相比,HbA1c变化的估计治疗差异及达到HbA1c<7%(<53 mmol/mol)且无临床显著或严重低血糖的比值比在年龄、族裔和种族亚组间相似。
- 未观察到统计学显著的治疗与亚组交互作用(所有情况下P>.05)。
- 两治疗组的低血糖发生率在数值上均较低,且在年龄、族裔和种族亚组间一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This post hoc analysis evaluated the impact of age, ethnicity, and race on efficacy and hypoglycemia outcomes with once-weekly insulin icodec (icodec) vs once-daily (OD) basal insulin comparators, leveraging data from the ONWARDS 1 to 5 phase 3a clinical trials. METHODS: Efficacy and hypoglycemia outcomes were assessed within each trial in insulin-naive (ONWARDS 1, 3, and 5) and insulin-experienced (ONWARDS 2 and 4) adults (≥18 years) with type 2 diabetes across subgroups of age (<55, 55-64, and ≥65 years), ethnicity (Hispanic/Latino and non-Hispanic/Latino), and race (Asian, Black/African American, White, Other). The primary outcome was the change in glycated hemoglobin (HbA1c) from baseline to planned end of treatment. Other outcomes assessed included the achievement of HbA1c <7% (<53 mmol/mol) without clinically significant or severe hypoglycemia and the number of clinically significant or severe hypoglycemic episodes. RESULTS: Across all trials, the estimated treatment differences for change in HbA1c and the odds ratios for achieving HbA1c <7% (<53 mmol/mol) without clinically significant or severe hypoglycemia were similar across age, ethnicity, and race subgroups with icodec vs OD insulin (no statistically significant treatment by subgroup interactions were observed; P > .05 in all instances). Hypoglycemia rates were numerically low for both treatment groups and consistent across age, ethnicity, and race subgroups. CONCLUSION: The efficacy and hypoglycemia profile of icodec vs OD comparators was consistent across trial populations irrespective of age, ethnicity, or race.
引用
- Lingvay I, Bache JK, Desouza CV, et al. Efficacy and Hypoglycemia Profile of Once-weekly Insulin Icodec vs Once-daily Comparators Across Demographic Subgroups. J Clin Endocrinol Metab. 2025. PMID: 40102962. doi:10.1210/clinem/dgaf168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。